243 related articles for article (PubMed ID: 23650948)
1. Pleiotropic effects of PPARγ agonist on hemostatic activation in type 2 diabetes mellitus.
Ferroni P; Della-Morte D; Pileggi A; Riondino S; Rundek T; Ricordi C; Guadagni F
Curr Vasc Pharmacol; 2013 May; 11(3):338-51. PubMed ID: 23650948
[TBL] [Abstract][Full Text] [Related]
2. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
3. Review of the pleiotropic effects of peroxisome proliferator-activated receptor gamma agonists on platelet function.
Borchert M; Schöndorf T; Lübben G; Forst T; Pfützner A
Diabetes Technol Ther; 2007 Oct; 9(5):410-20. PubMed ID: 17931049
[TBL] [Abstract][Full Text] [Related]
4. Platelets as a novel target for PPARgamma ligands : implications for inflammation, diabetes, and cardiovascular disease.
Ray DM; Spinelli SL; O'Brien JJ; Blumberg N; Phipps RP
BioDrugs; 2006; 20(4):231-41. PubMed ID: 16831022
[TBL] [Abstract][Full Text] [Related]
5. The platelet as a therapeutic target for treating vascular diseases and the role of eicosanoid and synthetic PPARgamma ligands.
O'Brien JJ; Ray DM; Spinelli SL; Blumberg N; Taubman MB; Francis CW; Wittlin SD; Phipps RP
Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):68-76. PubMed ID: 17164134
[TBL] [Abstract][Full Text] [Related]
6. The Potential Roles of Post-Translational Modifications of PPARγ in Treating Diabetes.
Ji X; Zhang W; Yin L; Shi Z; Luan J; Chen L; Liu L
Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551260
[TBL] [Abstract][Full Text] [Related]
7. Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma.
Sauer S
Trends Pharmacol Sci; 2015 Oct; 36(10):688-704. PubMed ID: 26435213
[TBL] [Abstract][Full Text] [Related]
8. Advances on PPARγ Research in the Emerging Era of Precision Medicine.
Lu P; Zhao Z
Curr Drug Targets; 2018; 19(6):663-673. PubMed ID: 28641522
[TBL] [Abstract][Full Text] [Related]
9. Does Thiazolidinedione therapy exacerbate fluid retention in congestive heart failure?
Goltsman I; Khoury EE; Winaver J; Abassi Z
Pharmacol Ther; 2016 Dec; 168():75-97. PubMed ID: 27598860
[TBL] [Abstract][Full Text] [Related]
10. Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes.
Akbiyik F; Ray DM; Gettings KF; Blumberg N; Francis CW; Phipps RP
Blood; 2004 Sep; 104(5):1361-8. PubMed ID: 15130939
[TBL] [Abstract][Full Text] [Related]
11. Insulin resistance and PPAR insulin sensitizers.
Bhatia V; Viswanathan P
Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.
Cho N; Momose Y
Curr Top Med Chem; 2008; 8(17):1483-507. PubMed ID: 19075761
[TBL] [Abstract][Full Text] [Related]
13. Can PPARgamma agonists have a role in the management of obesity-related hypertension?
Chetty VT; Sharma AM
Vascul Pharmacol; 2006 Jul; 45(1):46-53. PubMed ID: 16713364
[TBL] [Abstract][Full Text] [Related]
14. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectives.
Chiarelli F; Di Marzio D
Vasc Health Risk Manag; 2008; 4(2):297-304. PubMed ID: 18561505
[TBL] [Abstract][Full Text] [Related]
16. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
Defronzo RA; Mehta RJ; Schnure JJ
Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
[TBL] [Abstract][Full Text] [Related]
17. Thiazolidinediones as antidiabetic agents: A critical review.
Nanjan MJ; Mohammed M; Prashantha Kumar BR; Chandrasekar MJN
Bioorg Chem; 2018 Apr; 77():548-567. PubMed ID: 29475164
[TBL] [Abstract][Full Text] [Related]
18. [Recent trends in PPARgamma agonist development of thiazolidinediones and non-thiazolidinediones].
Tanaka T
Nihon Rinsho; 2010 Feb; 68(2):249-55. PubMed ID: 20158092
[TBL] [Abstract][Full Text] [Related]
19. PPARγ signaling and emerging opportunities for improved therapeutics.
Wang S; Dougherty EJ; Danner RL
Pharmacol Res; 2016 Sep; 111():76-85. PubMed ID: 27268145
[TBL] [Abstract][Full Text] [Related]
20. PPARγ ligands and their therapeutic applications: a patent review (2008 - 2014).
Takada I; Makishima M
Expert Opin Ther Pat; 2015 Feb; 25(2):175-91. PubMed ID: 25416646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
